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gust 26, 2013.he purpose of this study was to examine the incidence and outcomes of percutaneous coronary intervention (PCI)
performed in patients who had not received pre-procedural aspirin.Background Aspirin is an essential component of peri-PCI pharmacotherapy. Previous studies suggest that pre-procedural aspirin
is not administered to a clinically signiﬁcant number of patients undergoing PCI.Methods We evaluated the incidence of PCIs performed without pre-procedural aspirin use among patients undergoing PCI
from January 2010 through December 2011 at 44 hospitals in Michigan. Propensity-matched multivariate analysis
was used to adjust for the nonrandom use of aspirin.Results Our study population comprised 65,175 patients, of whom 4,640 (7.1%) did not receive aspirin within 24 h before
undergoing PCI. Aspirin nonreceivers were more likely to have had previous gastrointestinal bleeding or to present
with cardiogenic shock or after cardiac arrest. In the propensity-matched analysis, absence of aspirin before PCI was
associated with a higher rate of death (3.9% vs. 2.8%; odds ratio: 1.89 [95% conﬁdence interval: 1.32 to 2.71],
p < 0.001) and stroke (0.5% vs. 0.1%; odds ratio: 4.24 [95% conﬁdence interval: 1.49 to 12.11], p ¼ 0.007) with no
difference in need for transfusions. This association was consistent across multiple pre-speciﬁed subgroups.Conclusions A signiﬁcant number of patients do not receive aspirin before undergoing PCI. Lack of aspirin before PCI was
associated with signiﬁcantly increased in-hospital mortality and stroke. Our study results support the need for quality
efforts focused on optimizing aspirin use before PCI. (J Am Coll Cardiol 2013;62:2083–9) ª 2013 by the
American College of Cardiology FoundationAspirin (ASA) has been the cornerstone of procedural and
post-procedural therapy in patients undergoing percuta-
neous coronary intervention (PCI) since the early days of the
procedure (1–4). The beneﬁts of pre-PCI ASA are related
to its antiplatelet effects and the modulation of vascular
inﬂammation in response to vascular injury after PCI (5).
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; revised manuscript received August 17, 2013,outcomes has never been studied in large randomized
controlled trials, there is signiﬁcant evidence to support its
beneﬁt in this population (6–8).
Multiple studies, including data from the CRUSADE
(Can Rapid Risk Stratiﬁcation of Unstable Angina Pati-
ents Suppress Adverse Outcomes With Early Imple-
mentation of the ACC/AHA Guidelines) initiative, suggest
that a small but clinically important subgroup of patients
undergo PCI without receiving pre-procedural ASA (9,10).
Although ASA is relatively safe, widely available, and in-
expensive (11,12), there are a number of reasons for which
ASA might be withheld before a procedure. These include
but are not limited to: the inability to take oral ASA,
omission of ASA therapy while the patient is being rushed
to the catheterization laboratory, true contraindications such
as ASA-induced anaphylaxis, as well as perceived or relative
contraindications such as previous bleeding, gastritis, peptic
ulcer disease, renal dysfunction, ASA-exacerbated respira-
tory tract disease, and ASA-induced urticaria (13,14). To
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2084the best of our knowledge, there
have been no studies that speciﬁ-
cally addressed the association
between ASA nonuse before PCI
and in-hospital outcomes in the
contemporary era. A better un-
derstanding of the incidence and
clinical implications of pre-PCI
ASA nonuse might be helpful
in shaping a strategy to manage
such patients, including the use
of desensitization therapy, provi-
sion of alternative dual antiplatelet
regimens, or considerations for
surgical revascularization.Accordingly, we evaluated the frequency and implications
of pre-procedural ASA nonuse in patients undergoing PCI.
We used data from a large statewide quality improvement
initiative, The Blue Cross Blue Shield of Michigan
Cardiovascular Consortium (BMC2) registry.
Methods
Patient population and data collection. BMC2 is
a prospective, multicenter registry that collects demographic,
clinical, and procedural data from consecutive PCI cases at
all nonfederal hospitals in the state of Michigan. The details
of the BMC2 registry and its data collection and auditing
process have been described previously (15,16). Brieﬂy,
procedural data on all patients undergoing PCI at partici-
pating hospitals are collected by using standardized data
collection forms. Baseline data include clinical, demo-
graphic, procedural, and angiographic characteristics as well
as medications used before, during, and after the procedure;
information on in-hospital outcomes is also collected.
All data elements have been prospectively deﬁned, and the
protocol was approved by local institutional review boards at
each of the participating hospitals. In addition to a random
audit of 2% of all cases, medical records of all patients
undergoing multiple procedures or coronary artery bypass
grafting (CABG) and of patients who died in the hospital
are reviewed routinely to ensure data accuracy. ASA
nonreceivers were deﬁned as patients who did not take or
receive ASA within the 24 h before the procedure.
Contraindication to ASA was as per physician documenta-
tion and assumed to be present if the treating physician
made a notation in the patient chart that the risk of ASA
therapy outweighed any potential beneﬁt due to the presence
of an allergy or a medical condition.
Statistical analysis and study endpoints. The key study
endpoints were in-hospital mortality (deﬁned as death from
any cause before discharge) and need for transfusion. Secon-
dary endpoints include post-procedure myocardial infarction,
stroke, repeat target lesion PCI, emergent CABG, any
CABG, vascular complications, contrast-induced nephrop-
athy (CIN), and new renal dysfunction requiring dialysis.Statistical comparisons of baseline characteristics bet-
ween ASA receivers and nonreceivers were performed by
using Fisher exact tests for categorical variables and
Student t tests for continuous variables. We used propen-
sity matching to adjust for the nonrandom absence of
ASA before PCI. A generalized propensity score was esti-
mated by using logistic regression models, with pre-procedural
administration of ASA as the outcome, and including baseline
clinical history and presentation characteristics as predictors
(covariates are listed in Table 1). The propensity score was
estimated based on reduced logistic regression models for cases
with missing covariate data in which <3 covariate values
were missing (17). A propensity-matched cohort was con-
structed with ASA receivers and nonreceivers matched on
a 1:1 basis within a caliper 0.05 SD of the propensity score.
After propensity matching, 4,008 patients were selected
for each group for a total analysis population of 8,016.
To assess the adequacy of matching and covariate balance
between the 2 groups, we examined the standardized
differences for the included baseline covariates in the
matched cohort. After matching, none of the covariates had
a standardized difference that exceeded 10% (Online Fig. 1).
For further conﬁrmation of balanced matching, we assessed
for the differences in an unrelated outcome (CIN) that
would not be expected to be inﬂuenced by ASA use. Pres-
ence of a differing outcome between the 2 groups in the
absence of biological plausibility would be suggestive of
residual confounding. Finally, we performed a sensitivity
analysis to examine the sensitivity of the results, particularly
the primary outcome of in-hospital mortality, to unmeasured
confounders (18). Multivariate logistic regression models
were ﬁtted in the propensity-matched cohort with a number
of in-hospital outcomes as dependent variables and pre-
procedural ASA as the covariate of interest, adjusting for
baseline clinical and presentation covariates used for
matching.
We further tested the impact of ASA nonuse on mortality
in multiple pre-speciﬁed subgroups: age, sex, presentation of
coronary artery disease (ST-segment elevation myo-
cardial infarction, non–ST-segment elevation acute coronary
syndrome, and stable angina), and presence or absence of
shock, cardiac arrest, and diabetes. Subgroup analysis was
performed both by using the Fisher exact test for the
univariate analysis and by adjusting for signiﬁcant baseline
covariates through multivariate logistic regression models
ﬁtted separately within each subgroup. Multivariate
subgroup analysis was performed within the propensity-
matched cohort, with the covariates chosen for inclusion
in the models based on their signiﬁcance in the overall
multivariate mortality model at a signiﬁcance level of
alpha ¼ 0.1. For all other analyses, a nominal p value <0.05
was considered statistically signiﬁcant, and no adjustments
were made for multiple comparisons. All analyses were
performed by using R version 2.14.1 (R Foundation for
Statistical Computing, Vienna, Austria).
Table 1 Baseline Characteristics of Unmatched and Propensity-Matched Cohorts
Variable
Unmatched Cohort Propensity-Matched Cohort
ASA Nonreceivers
(n ¼ 4,640)
ASA Receivers
(n ¼ 60,535) p Value
ASA Nonreceivers
(n ¼ 4,008)
ASA Receivers
(n ¼ 4,008) p Value
Mean age (yrs) 65.3 65.9 <0.001 65.9 66.0 0.73
Male 61.3% 66.4% <0.001 61.3% 60.3% 0.37
No insurance coverage 4.9% 5.2% <0.001 5.1% 5.8% 0.13
Current smoker 30.0% 29.3% 0.33 30.9% 31.3% 0.74
Body mass index (kg/m2) 30.3 30.6 0.02 30.3 30.3 0.98
Hypertension 82.8% 85.2% <0.001 83.8% 83.3% 0.57
Diabetes mellitus 36.6% 37.2% 0.38 36.5% 35.9% 0.56
Previous myocardial infarction 36.4% 35.7% <0.001 28.0% 28.0% 1.00
Previous PCI 37.5% 45.4% <0.001 36.9% 36.6% 0.87
Previous cardiac arrest 3.7% 2.4% <0.001 3.6% 4.3% 0.11
Congestive heart failure 13.9% 15.6% 0.003 15.0% 14.6% 0.57
Gastrointestinal bleeding 1.7% 1.1% <0.001 1.9% 2.2% 0.34
Valve disease 3.9% 5.5% <0.001 4.3% 4.5% 0.83
Extracardiac vascular disease 26.4% 26.4% 0.99 26.8% 27.6% 0.44
Atrial ﬁbrillation 8.5% 10.7% <0.001 9.4% 9.3% 0.91
Chronic obstructive pulmonary disease 20.5% 18.3% <0.001 21.7% 21.4% 0.83
End-stage renal disease 2.6% 2.2% 0.13 2.6% 2.5% 0.72
Left ventricular ejection fraction 50.6% 51.7% <0.001 50.6% 50.2% 0.20
Baseline creatinine (mg/dl) 1.2 1.1 0.005 1.2 1.2 0.77
Baseline glomerular ﬁltration rate (ml/min) 76.5 78.7 <0.001 76.6 76.7 0.97
Baseline hemoglobin (g/dl) 13.3 13.4 <0.001 13.3 13.3 0.21
STEMI <12 h 15.3% 13.1% <0.001 15.0% 15.3% 0.78
STEMI (unstable, >12 h) 0.9% 0.7% 0.06 0.9% 0.9% 1.00
STEMI (stable, >12 h) 0.4% 0.4% 0.90 0.4% 0.3% 0.56
STEMI (after thrombolysis) 0.6% 0.3% 0.05 0.7% 0.9% 0.53
Rescue PCI for STEMI 0.7% 0.6% 0.42 0.6% 0.7% 1.00
Non–ST-segment elevation acute coronary syndrome 40.2% 46.8% <0.001 44.1% 44.3% 0.93
Staged PCI 4.8% 6.9% <0.001 4.8% 5.2% 1.00
Cardiogenic shock 4.0% 1.4% <0.001 3.9% 4.5% 0.16
Cardiac arrest 5.1% 1.5% <0.001 5.1% 5.5% 0.45
Baseline demographic, clinical characteristics, and clinical presentations of both the unmatched patients and the propensity-matched cohort of patients receiving aspirin (ASA) compared with ASA nonusers.
PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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Patient population. Among a total of 65,175 PCIs per-
formed in 44 institutions in Michigan between January 2010
and December 2011, ASA was not administered to 4,640
(7.1%) of the patients before PCI. Of those patients who did
not receive ASA, only 495 (10.7%) had a documented
contraindication to ASA use. Among the ASA nonreceivers,
ST-segment elevation myocardial infarction was the pre-
senting diagnosis in 830 (17.9%) and non–ST-segment
elevation acute coronary syndrome in 1,866 (40.2%)
patients; 1,447 (31.2%) patients underwent PCI for stable
coronary artery disease, with the remainder undergoing PCI
for multiple other indications. A signiﬁcant number of
patients who did not receive ASA before PCI were started
on ASA after the procedure (n ¼ 2,111 [45.5%]).
Baseline demographic, clinical, and presentation charac-
teristics of the 2 groups are presented in Table 1. Most of
the baseline demographic and clinical characteristics were
statistically different for the unmatched groups given the
large sample size. The most notable clinically signiﬁcantdifferences included previous PCI, which was more common
in ASA receivers, and previous gastrointestinal bleeding,
which was more frequent in ASA nonreceivers. Moreover,
ASA nonreceivers were more likely to undergo primary PCI
and to present in cardiogenic shock or after a cardiac arrest.
There was no difference in baseline renal function or
hemoglobin levels between the 2 groups.
Unadjusted outcomes of ASA receivers compared with
nonreceivers are summarized in Table 2. Patients who did
not receive ASA were more likely to die, have a stroke, or
undergo CABG. Similarly, the transfusion rate was higher
in those who did not receive ASA.
Propensity score-matched data. A total of 8,016 patients
were selected in 1:1 propensity score matching, with 4,008
patients in the group receiving ASA before PCI and an
equal number in the group of ASA nonusers. The C-statistic
for the propensity score model was 0.69. The 2 groups were
well matched, with no statistically signiﬁcant difference in
the baseline demographic and clinical characteristics,
including clinical presentation (Table 1, Online Fig. 1).
Table 2 Unmatched Data on In-Hospital Outcomes
In-Hospital Outcome
ASA Nonreceivers
(%)
ASA Receivers
(%) p Value
Death 3.9 1.2 <0.001
Transfusion 5.3 3.3 <0.001
Post-procedural
myocardial infarction
0.7 0.5 0.18
CABG 1.5 0.9 0.00044
Emergent CABG 0.2 0.2 1.00
Stroke 0.5 0.2 0.02
Repeat PCI to the same
lesion
0.5 0.6 0.41
Vascular complications 3.4 2.9 0.06
Contrast-induced
nephropathy
4.0 2.5 <0.001
New renal dysfunction
requiring dialysis
0.5 0.2 0.0047
Unadjusted in-hospital outcomes of patients receiving ASA compared with those not receiving ASA
before PCI.
CABG ¼ coronary artery bypass grafting; other abbreviations as in Table 1.
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2086Although procedural medications were not included in the
covariates used for propensity matching, no major differ-
ences were noted in the use of procedural antiplatelet and
anticoagulation agents (Online Table 1). Most notably,
the use of glycoprotein IIb/IIIa inhibitors within the 24 h
before and during the procedure was not different between
the 2 groups. ASA nonusers were more likely to be treated
with prasugrel and ticagrelor, whereas clopidogrel use was
more common in ASA receivers.
Adjusted outcomes in the propensity-matched cohort are
displayed in Table 3 and Figure 1. After adjusting for
baseline confounders, patients who underwent PCI without
receipt of ASA were more likely to die (3.9% vs. 2.8%; odds
ratio [OR]: 1.89 [95% conﬁdence interval (CI): 1.32 to
2.71], p < 0.001) or have a stroke (0.5% vs. 0.1%; OR: 4.24
[95% CI: 1.49 to 12.11], p ¼ 0.007). Death adjudicated
with a cardiovascular primary cause occurred in 93 (2.32%)Table 3 Propensity-Matched Data on In-Hospital Outcomes
In-Hospital Outcome
ASA Nonreceivers
(%)
ASA Receivers
(%) p Value
Death 3.87 2.79 0.0005
Transfusion 5.71 5.54 0.53
Post-procedural myocardial
infarction
0.70 0.50 0.22
CABG 1.65 1.00 0.07
Emergent CABG 0.20 0.20 0.93
Stroke 0.52 0.15 0.007
Repeat PCI to the same
lesion
0.50 0.47 0.73
Vascular complications 3.47 4.07 0.40
Contrast-induced
nephropathy
4.37 4.14 0.25
New renal dysfunction
requiring dialysis
0.47 0.60 0.52
Comparison of in-hospital outcomes in propensity-matched groups of ASA receivers versus ASA
nonreceivers.
Abbreviations as in Table 1.patients receiving ASA and 121 (3.02%) ASA nonreceivers
(OR: 1.31 [95% CI: 0.99 to 1.74], p ¼ 0.06). There was
also a trend toward an increased risk for CABG (OR: 1.52,
p ¼ 0.07) that did not reach statistical signiﬁcance. No
difference in the need for transfusions, post-procedural
myocardial infarction, repeat PCI to the same lesion, or
vascular complications was observed between the 2 groups.
These results were preserved in multiple pre-speciﬁed
subgroups (Fig. 2).
To assess whether disparities in the baseline health status
not captured by the covariates included in the dataset might
have confounded our analysis, the incidence of CIN, which
is presumed to be physiologically unrelated to ASA use, was
evaluated in the matched cohort. No difference in the
unrelated outcome of CIN (OR: 1.17 [95% CI: 0.89 to
1.54]) was observed.
Furthermore, on sensitivity analysis, our results were
robust to the effect of an unmeasured confounder. A
number of scenarios were evaluated assuming unmeasured
confounders varying in both the extent of disparity in the
prevalence between the 2 groups of ASA receivers and
nonreceivers and in the effect size (OR) on outcomes. Only
in the most extreme scenarios (i.e., those assuming both
very large effect size and disparity in prevalence) was the
association between mortality and nonreceipt of ASA
rendered statistically insigniﬁcant after accounting for
confounder effects (Online Table 2).
Discussion
The key ﬁnding of our study is that a signiﬁcant number of
patients do not receive ASA before undergoing PCI despite
the Class I recommendations for pre-procedural ASA in
both the American College of Cardiology/American Heart
Association and European Society of Cardiology guidelines
for PCI (19–21). This ﬁnding seems to occur across all
presentations, including stable coronary artery disease. Ab-
sence of ASA before PCI seems to be associated with an
increased risk of mortality and stroke.
The underuse of ASA before PCI is especially sur-
prising because only a small proportion of ASA non-
receivers (10.7%) had a documented contraindication. It
is possible that some patients did not receive ASA due
to the severity of their illness and presence of factors such
as cardiac arrest or shock that would prevent oral admin-
istration of ASA and in whom rectal administration was
not considered. These and other factors, such as the failure
to recognize the importance of pre-procedural ASA by the
primary caregivers, may account for the lack of ASA
administration in patients being rushed to the catheteriza-
tion laboratory for emergent procedures. Inappropriate
reasons for withholding ASA, such as a distant history of
gastrointestinal bleeding, are also likely to contribute, as
suggested in previous studies (14).
Furthermore, we observed an increased risk of all-cause
in-hospital mortality and stroke in association with the
Figure 1 Propensity-Matched In-Hospital Outcomes
Forest plot of the odds ratios and their 95% conﬁdence intervals for the major in-hospital outcomes among propensity-matched groups of aspirin (ASA) nonreceivers compared
with ASA receivers before percutaneous coronary intervention (PCI). CABG ¼ coronary artery bypass grafting; CVA ¼ cardiovascular accident; MI ¼ myocardial infarction.
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2087absence of ASA use before PCI. Although part of this
increased rate of death in the cohort of ASA nonreceivers
could be driven by the more acute and critical clinical
presentation, adjusting for these differences did not elimi-
nate the risk associated with the absence of ASA use. This
was further demonstrated in the subgroup analysis, in which
the higher risk of death in ASA nonreceivers persisted in
patients presenting without cardiogenic shock and who did
not have a cardiac arrest before presentation. Although the
number of deaths in the stable angina population was too
low for an adjusted analysis, the signal of increased unad-
justed mortality in this cohort in association with ASA
nonuse is noteworthy. It is likely that the absence of ASA
before PCI increases the risk of ischemic events, and this is
the most probable reason for the higher rate of in-hospital
mortality and stroke that was observed in our study. This
association could be further supported by the strong signal
for increased in-hospital cardiovascular death in the ASA
nonusers group, which could be explained by the possibilityFigure 2 Primary Outcome Subgroup Analysis
Forest plot of the odds ratios and their 95% conﬁdence intervals of in-hospital mortality in
reﬂects the risk adjusted outcomes in the propensity-matched subsets. *Adjusted analysis
ASA = aspirin; STEMI ¼ ST-segment elevation myocardial infarction.that patients who did not receive ASA were more prone to
local platelet activation and thrombosis that could have led
to acute closure or stent thrombosis (events that are often
fatal). Furthermore, suboptimal results may have manifested
as a greater degree of myocardial injury and larger infarc-
tions, with a resulting increase in the risk of arrhythmic
events. Moreover, almost one-half of the patients who did
not receive ASA before the procedure received it thereafter,
which is likely to have negated part of the deleterious impact
of nonreceipt of ASA before the procedure.
The ﬁndings of our study add to and signiﬁcantly extend
previous, similar work (3,6,9,11). We identiﬁed a clinically
signiﬁcant proportion of patients not receiving ASA before
undergoing contemporary PCI, a ﬁnding that is especially
striking because all hospitals included in the study partici-
pate in an active, multicenter quality improvement collabo-
rative. It also conﬁrms previous ﬁndings that associate not
receiving pre-procedural ASA with worse outcomes, most
notably in-hospital death. Our results gain furtherkey subgroups. The left panel reﬂects the unadjusted outcomes, and the right panel
was not performed for stable angina population due to an exceedingly low event rate.
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2088signiﬁcance in the face of recent data from the WOEST
(What Is the Optimal Antiplatelet and Anticoagulant
Therapy in Patients With Oral Anticoagulation and Coro-
nary Stenting) study, which suggested that omitting ASA
from dual chronic antiplatelet therapy in patients on oral
anticoagulant agents undergoing PCI is associated with less
bleeding and no increase in the risk of thrombotic events
compared with triple therapy (22). Our study predated the
WOEST trial, and thus its ﬁndings could not have been
inﬂuenced by this trial. More importantly, establishing an
association between lack of pre-procedural ASA and worse
in-hospital outcomes re-emphasizes the role of pre-PCI
ASA and serves as a reminder not to apply the results of
the WOEST study liberally across all patients undergoing
PCI. It is important to recognize that our study focused on
pre-procedural ASA, whereas the WOEST trial explored
the utility of chronic post-PCI ASA in patients who were
treated with long-term clopidogrel and warfarin.
Study limitations. The speciﬁc reasons for the contrain-
dication to receiving ASA are unavailable in the BMC2
database. Moreover, not receiving ASA before the proce-
dure, as was deﬁned in the study, might have been difﬁcult
to conﬁrm in patients presenting in critical conditions such
as after cardiac arrest or in cardiogenic shock. Similarly, the
dose and exact timing of ASA administration might have
been difﬁcult to conﬁrm in patients who self-administered
ASA before presentation. However, these factors would
have likely biased our ﬁndings toward the null. Moreover,
the records of all patients who died were audited, and it is
unlikely that there was a systematic error in abstracting ASA
data. In addition, our ﬁndings are subject to unmeasured
confounders that may skew the observed associations.
We believe that our data should be considered hypothesis
generating. Triggered by our ﬁndings, similar studies to
further test our hypothesis, as well as others to analyze the
long-term outcomes associated with ASA nonuse before
and after PCI, should be considered. If our results are
replicated, this would justify more focused efforts to opti-
mize ASA use and shape a strategy to manage patients with
true contraindications or intolerances to ASA therapy, in-
cluding the need for desensitization therapy, consideration
of other options for dual antiplatelet therapy, or possible
surgical revascularization, which would not require ASA
pre-treatment.
Conclusions
A signiﬁcant number of patients do not receive ASA before
undergoing PCI. ASA nonreceivers in our study were more
likely to experience adverse outcomes, including a higher
rate of in-hospital death and stroke. Further studies are
needed to conﬁrm our ﬁndings and motivate quality efforts
focused on optimizing ASA use before PCI, as recom-
mended in the American College of Cardiology/American
Heart Association and European Society of Cardiology
guidelines for PCI (19–21).Acknowledgments
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